Purpose: To compare the accuracy of planar scintigraphy, single photon emission computed tomography (SPECT), SPECT-CT, and positron emission tomography (PET) with C-11 methionine for the pre-operative detection of parathyroid adenomas.
Materials And Methods: We retrospectively evaluated the pre-operative studies of 60 patients with primary (n=56) and secondary (n=4) hyperparathyroidism. In 25/60 patients (Group 1), only planar scans were obtained, and additional SPECT and SPECT-CT were carried out in 35/60 patients (Group 2). PET or PET-CT with C-11 methionine was conducted in 8/60 patients (Group 3).
Results: The results of the planar scans (Group 1) were true positive in 19/25 patients and false negative in 6/25 patients (sensitivity per patient, 76%). Histopathology confirmed 27 adenomas and two hyperplasia. Planar imaging identified 20/29 of these pathologies, whereas 9/29 were missed (sensitivity per adenoma, 69%). SPECT (Group 2) results were true positive in 34/35 patients and false negative in only one case (sensitivity per patient, 97%). On a lesion-based analysis, 38 adenomas were identified, and two were missed (sensitivity per adenoma, 95%). The sensitivities of SPECT and SPECT-CT were equal; however, SPECT-CT provided superior topographic information. C-11 methionine PET (Group 3) results were true positive in all eight patients. In one case, surgery confirmed two ipsilateral adenomas, only one of which was identified by PET (sensitivity per patient, 100%; per adenoma, 88.9%).
Conclusion: SPECT is superior to planar imaging. SPECT-CT has identical sensitivity compared to SPECT alone, but it provides additional topographic information. The sensitivity of PET appears to be even higher compared to SPECT. In the case of negative scintigraphic findings and proven hyperparathyroidism, additional C-11 methionine PET or PET-CT is recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4261/1305-3825.DIR.3486-10.1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
11C-Methionine PET/CT in Cryptococcus Meningoencephalitis.
Clin Nucl Med
February 2025
From the Department of Radiology, Tokushima University Hospital, Tokushima, Japan.
A 70-year-old man experienced an epileptic seizure. Subsequent MRI performed on close examination revealed high signal in the left occipital cortex on fluid-attenuated inversion recovery. Gadolinium contrast indicated enhancement along the cortex.
View Article and Find Full Text PDFC-Methionine uptake in meningiomas after stereotactic radiotherapy.
Ann Nucl Med
August 2024
Department of Neurosurgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700RB, Groningen, The Netherlands.
Objective: C-Methionine positron emission tomography (MET-PET) is used for stereotactic radiotherapy planning in meningioma patients. The role of MET-PET during subsequent follow-up (FU) is unclear. We analyzed the uptake of C-Methionine before and after stereotactic radiotherapy (SRT) in patients with a complex meningioma and investigated if there was a difference between patients with progressive disease (PD) and stable disease (SD) during FU.
View Article and Find Full Text PDFReal-world experience with 11C-methionine positron emission tomography in the management of acromegaly.
Eur J Endocrinol
March 2024
Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, United Kingdom.
Background: L-[methyl-11C]-methionine-positron emission tomography (Met-PET) is a potentially important imaging adjunct in the diagnostic workup of pituitary adenomas, including somatotroph tumors. Met-PET can identify residual or occult disease and make definitive therapies accessible to a subgroup of patients who would otherwise require lifelong medical therapy. However, existing data on its use are still limited to small case series.
View Article and Find Full Text PDFClinical decision-making based on 11C-methionine PET in recurrent Cushing's disease with equivocal MRI findings.
J Neurosurg
December 2023
1Hypothalamic and Pituitary Center, Moriyama Memorial Hospital, Tokyo.
Article Synopsis
- The study focused on using 11C-methionine positron emission tomography (MET-PET) to help diagnose and locate recurrent tumors in patients with Cushing's disease who had ambiguous MRI results after several surgeries.
- A total of 15 patients were evaluated, all of whom had undergone multiple treatments, but their MRI scans could not reliably differentiate between tumor recurrence and post-surgical changes.
- MET-PET findings led to successful identification of tumors in some patients, guiding treatment decisions, including repeat surgeries and nonsurgical options like temozolomide for those not needing immediate surgery.
Diagnostic utility of C-methionine PET/CT in primary hyperparathyroidism in a UK cohort: A single-centre experience and literature review.
Clin Endocrinol (Oxf)
September 2023
Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
Objective: Primary hyperparathyroidism is a common endocrine disorder, with 80% of all cases usually caused by one single hyperfunctioning parathyroid adenoma. Conventional imaging modalities for the diagnostic work-up of primary hyperparathyroidism (PHPT) include ultrasound of the neck, 99mTc-sestamibi scintigraphy, and four-dimensional computed tomography (4D-CT). However, the role of other imaging modalities, such as 11C-methionine PET/CT, in the care pathway for PHPT is currently unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!